Neogenomics Inc (NASDAQ:NEO) shares traded -5.62% lower at $7.39 on Wall Street last session.
NEO stock price is now -10.43% away from the 50-day moving average and -42.32% away from the 200-day moving average. The market capitalization of the company currently stands at $951.05M.
On April 30, 2025, Leerink Partners Downgraded its previous ‘Outperform’ rating to ‘Market Perform’ on the stock keeping its target price maintained at $9, while ‘The Benchmark Company’ rates the stock as ‘Hold’
In other news, Kelly Michael Aaron, Director bought 5,000 shares of the company’s stock on May 27 ’25. The stock was bought for $38,000 at an average price of $7.60. Upon completion of the transaction, the Director now directly owns 5,000 shares in the company, valued at $36950.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 12 ’25, Pres & Chief Operating Officer Stone Warren bought 5,700 shares of the business’s stock. A total of $48,895 was incurred on buying the stock at an average price of $8.58. This leaves the insider owning 108,280 shares of the company worth $0.8 million. A total of 1.38% of the company’s stock is owned by insiders.
During the past 12 months, Neogenomics Inc has had a low of $6.08 and a high of $19.11. As of last week, the company has a debt-to-equity ratio of 0.68, a current ratio of 2.05, and a quick ratio of 1.94.
The net profit margin was -11.54% and return on equity was -8.57% for NEO.
